[Digital health applications and axial spondyloarthritis]

Digital health applications (DHA) can provide exercise therapy, behavioral interventions or patient education. These interventions are of high relevance in axial spondyloarthritis (axSpA). Therefore, axSpA represents a potentially promising area of DHA usage; however, no DHA has yet been officially approved for axSpA. Currently, the medical apps Axia and RheCORD Plus are in the DiGA approval track. So far, published study results are only available for Axia and appear promising. In addition to these apps, DHAs such as ViViRA or HelloBetter Chronic Pain are being tested in axSpA, and initial study results also show positive effects in this context. The use of DHAs in axSpA thus shows promising potential, although further research is needed to evaluate long-term effectiveness, cost-effectiveness and user acceptance.